OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis $0.03 +0.00 (+3.65%) As of 11:25 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About Emmaus Life Sciences Stock (OTCMKTS:EMMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Emmaus Life Sciences alerts:Sign Up Key Stats Today's Range$0.02▼$0.0350-Day Range$0.01▼$0.0552-Week Range$0.00▼$0.13Volume10,671 shsAverage Volume52,153 shsMarket Capitalization$1.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.Read More… Remove Ads Emmaus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreEMMA MarketRank™: Emmaus Life Sciences scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Emmaus Life Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Emmaus Life Sciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emmaus Life Sciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Emmaus Life Sciences has been sold short.Short Interest Ratio / Days to CoverEmmaus Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emmaus Life Sciences has recently decreased by 51.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmmaus Life Sciences does not currently pay a dividend.Dividend GrowthEmmaus Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the float of Emmaus Life Sciences has been sold short.Short Interest Ratio / Days to CoverEmmaus Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emmaus Life Sciences has recently decreased by 51.49%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentEmmaus Life Sciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Emmaus Life Sciences this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for EMMA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.42% of the stock of Emmaus Life Sciences is held by institutions.Read more about Emmaus Life Sciences' insider trading history. Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EMMA Stock News HeadlinesEmmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi ArabiaJanuary 29, 2025 | finance.yahoo.comEmmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Improved Quarterly Financial ResultsNovember 23, 2024 | finanznachrichten.deLying in hospital… staring at the light"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 17, 2025 | Porter & Company (Ad)Emmaus Life Sciences Reports Improved Quarterly Financial ResultsNovember 19, 2024 | prnewswire.comMike Johnson impersonates Trump: ‘Make it too big to rig’November 7, 2024 | uk.news.yahoo.comQ&A with Madison County candidates for Probate JudgeOctober 31, 2024 | msn.comEvanescence’s Amy Lee Makes Official Presidential EndorsementOctober 31, 2024 | msn.comEmmaus Life Sciences appoints new board memberOctober 6, 2024 | investing.comSee More Headlines EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed this year? Emmaus Life Sciences' stock was trading at $0.0085 at the beginning of the year. Since then, EMMA shares have increased by 234.1% and is now trading at $0.0284. View the best growth stocks for 2025 here. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emmaus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX). Company Calendar Today3/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:EMMA CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,730,000.00 Net Margins-17.11% Pretax MarginN/A Return on EquityN/A Return on Assets-12.66% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.12 Sales & Book Value Annual Sales$29.60 million Price / Sales0.06 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares63,866,000Free Float41,513,000Market Cap$1.75 million OptionableNot Optionable Beta6.47 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:EMMA) was last updated on 3/17/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emmaus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
